At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 168 enrolled
Drug / intervention
AV7909 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers
In Brief
A Phase 2 clinical trial evaluating AV7909 and BioThrax for Anthrax. Completed, enrolled 168 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess the safety and immunogenicity of an anthrax vaccine. The vaccine schedule and dose will also be assessed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnthrax
CountriesUnited States
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionFeb 2014
Study CompletionDec 2014
TodayJul 2026
First PostedJan 18, 2013
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.5 years ago
Interventions
AV7909biological
Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
BioThraxbiological